SortAI
Your AI Designs Sequences. We Tell You Which Ones Actually Work.
Before you spend a dollar on recombinant protein production, SortAI converts your computationally designed sequence panels into ranked, training-ready biological data, positive binders, negative populations, and functional signal, all in one engagement.
The Wet Lab Is Where AI Drug Discovery Stalls.
AI antibody platforms generate campaigns of hundreds to thousands of designed sequences. But the CRO infrastructure built to validate them was designed around single-candidate drug programs, full recombinant expression on every sequence, one at a time, before any biological filtering has been applied.
The result: slow cycles, wasted budget, and a model that can’t improve until the lab catches up.
Most CROs make whatever you send them. SortAI filters it first.
One Engagement. The Full Triage Picture.
SortAI is Mosaic’s yeast-based validation workflow, purpose-built for AI-generated sequence panels. Here’s what a single engagement delivers:
Sequence Liability Review at Intake
Before anything enters the funnel, Mosaic scientists review your panel for known CDR liabilities, cysteines, aggregation motifs, poor expression signals, that most AI algorithms don’t screen for. Bad sequences get flagged before they waste wet lab capacity.
Yeast-Based Selection at Library Scale
Multi-round selection across panels ranging from hundreds to tens of millions of sequences, with NGS at each round to track population dynamics. Progressive triage without committing to full protein production upfront.
Negative Data Returned, Not Discarded
Every round generates a negative population. We sequence and return those alongside your ranked positive binders. For model retraining, what didn’t bind is half the story, and SortAI is one of the few workflows built to treat it as a deliverable.
Function Pulled Forward
Candidates that pass binding are immediately pressure-tested for biological activity through cell-based functional screening, not weeks later after expensive downstream work.
Binding. Affinity. Epitope Binning. Developability. Function. Together.
Most competitors don’t offer this scope as a defined service. Teams trying to assemble it piecemeal need multiple vendors, multiple timelines, and multiple data sets. SortAI delivers the complete picture in a single engagement.
Faster Cycles. A Fraction of the Cost.
A production-centric competitor workflow covering binding and affinity alone takes approximately 7 weeks and costs multiples of a full SortAI engagement, which goes all the way through developability and cell-based functional screening.
6 weeks (Sequence enrichment and delivery for model training 14 weeks) Full engagement: binding, affinity, epitope binning, developability, and cell-based functional screening
Detailed pricing available upon request.
We Know This Space.
216+
Discovery programs completed to date.
80%
Of scientific staff hold advanced degrees (PhD/MS).
504+
Peer-reviewed publications and patents authored by Mosaic scientists.
50+
Experienced scientists and program leaders.
100%
Research conducted in the USA.
Experts From the World’s Top Organizations
Eric Furfine, PhD
Chief Scientific Officer
Led IPO-financed Phase 3 programs at Eleven Biotherapeutics. Built the Adnectin platform (acquired by BMS). Former VP at Regeneron contributing to Eylea development.
Tracy Mullen
Chief Strategy Officer
Former SVP Biopharma at Twist Bioscience (post-Abveris acquisition). Former CEO of Abveris. Antibody discovery leadership experience at Biogen and Adimab platform implementation.
Alexei Kazantsev, PhD
VP Protein Design and Engineering
Structural and chemical biology expert. Leads protein engineering and PK optimization at Mosaic. Prior research in RNA and protein structural biology using X-ray crystallography and SAXS.
Scott Glaser PhD
SVP, Biologics Discovery
30+ years in biologic drug discovery. Former Director of Antibody Therapeutics at Novartis (GNF) and senior leadership at Pfizer and Biogen. Contributor to 50+ discovery programs and co-inventor on 23 US patents.
Ready to Run Your Next Design Cycle Faster?
Tell us about your sequence panel and your program goals. Our scientific team will follow up to design an engagement around your specific workflow.
Start a conversation with our scientific team about your discovery program today